Roles of retroviral R regions in long terminal repeat-driven gene expression. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Roles of retroviral R regions in long terminal repeat-driven gene expression.

Diss Abstr Int [B]; 53(4):1708 1992. Unique Identifier : AIDSLINE ICDB/93688343
Cupelli LA; Yeshiva Univ.


Abstract: The R region of the retroviral long-terminal repeat (LTR) marks the site of transcription initiation of provirus RNAs and has been well characterized for its role in viral replication. In the human retroviruses, the R region also functions in the expression of viral genomes. A sequence within the R region of the human immunodeficiency virus type 1 (HIV-1), termed TAR, is critical for transactivation by the virally encoded transactivator protein, Tat. Although transactivation occurs at high levels in human cells, it does not occur in mouse cells. We have used mouse-human somatic cell hybrid lines to show that a factor present on human chromosome 12, or the long arm of chromosome 2, facilitates this transactivation when present in a mouse chromosome background. We have also demonstrated that a sequence within the R regions of the murine leukemia viruses, Akv and SL3, is necessary for max expression. Deletion of nucleotides +4 to +32 of the MuLV R region in LTR-CAT constructs demonstrated that this sequence contributes to transcription initiation and to some post-transcriptional process. A computer-generated secondary structure prediction revealed a possible stem-loop structure formed by this sequence at the RNA level. Comparison of retroviral R regions showed that there is a 90-100% conservation of the 5' 32 nucleotides of this region among MuLVs and some related retroviruses, and that this strong conservation maintains the predicted secondary structure. Specific mutations within the R region element were, therefore, designed to test the effects of altered secondary structure. These mutations indicated that both primary sequence and secondary structure seem to be important for this element's activity. Initiation of transcription seems to be dependent upon primary sequence and secondary structure, while the post-transcriptional component of the R element's activity seems to be more dependent upon secondary structure. In addition, the element seems to work best when positioned just 3' to the mRNA start site. Possibilities for the post-transcriptional component of activity include RNA stability, processing and transport. Precedents for the element's transcriptional activity are initiator elements, which represent binding sites for transcription factors on the DNA, and the TAR element, which responds to the Tat protein in a manner that is dependent upon RNA secondary structure. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No. AAD92-22540.)
Keywords: Animal Chloramphenicol Acetyltransferase/GENETICS Chromosomes, Human, Pair 12 Chromosomes, Human, Pair 2 *Gene Expression Gene Products, tat Genome, Viral Human HIV Long Terminal Repeat/*GENETICS Leukemia Viruses, Murine/GENETICS Mice Mutation Protein Processing, Post-Translational Protein Structure, Secondary Retroviridae/*GENETICS RNA, Viral/GENETICS Trans-Activation (Genetics) Transcription, Genetic THESISKWDanimalchloramphenicolacetyltransferase/geneticschromosomes,human,pair12chromosomes,human,pair2KWDgeneexpressiongeneproducts,tatgenome,viralhumanhivlongterminalrepeat/KWDgeneticsleukemiaviruses,murine/geneticsmicemutationproteinprocessing,post-translationalproteinstructure,secondaryretroviridae/KWDgeneticsrna,viral/geneticstrans-activation(genetics)transcription,geneticthesis
930530
M9350991

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .